Cargando…

CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125.

Detalles Bibliográficos
Autores principales:	Canney, P. A., Wilkinson, P. M., James, R. D., Moore, M.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1985
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977182/ https://www.ncbi.nlm.nih.gov/pubmed/2410004

Ejemplares similares

Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker.
por: Canney, P. A., et al.
Publicado: (1984)

Oncological markers CA-125, CA 19-9 and endometriosis
por: Fiala, Ludek, et al.
Publicado: (2018)

Serum CA19‐9, CA‐125 and CEA as tumor markers for mucinous ovarian tumors
por: Lertkhachonsuk, Arb‐aroon, et al.
Publicado: (2020)

Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.
por: Haglund, C.
Publicado: (1986)

A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA125 for the serological detection and management of epithelial ovarian cancer.
por: Dhokia, B., et al.
Publicado: (1986)

Oncofetal markers CA 19-9, CA 125 and SP1 in healthy children and in children with malignancy.
por: Heikinheimo, M., et al.
Publicado: (1990)

Sensitivity and specificity of microRNA-204, CA125, and CA19.9 as biomarkers for diagnosis of ovarian cancer
por: Ali, Fahmy T., et al.
Publicado: (2022)

Assessment of tumor markers CA 19-9, CEA, CA 125, and CA 242 for the early diagnosis and prognosis prediction of gallbladder cancer
por: Sinha, Seema Rani, et al.
Publicado: (2022)

Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy
por: Tuxen, M K, et al.
Publicado: (2001)

The effect of CA125 on metastasis of ovarian cancer: old marker new function
por: Yuan, Qin, et al.
Publicado: (2017)

The utility of tumor markers CA 125, CA 15-3, and CA 19-9 in assessing the response to therapy in pulmonary and pleural tuberculosis
por: Tascı, Canturk, et al.
Publicado: (2012)

The Value of CA 125 and CA72-4 in Management of Patients with Epithelial Ovarian Cancer
por: Fayed, Salah T., et al.
Publicado: (1998)

Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer
por: Gao, Yanfeng, et al.
Publicado: (2018)

The added value of CA125, HE4, and CA72-4 as markers for ovarian endometriosis diagnosis
por: Micu, Romeo, et al.
Publicado: (2023)

CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
por: Haglund, C., et al.
Publicado: (1994)

Combined Evaluation of AFP, CA15-3, CA125, CA19-9, and CEA Tumor Markers in Patients with Hepatitis B and C
por: ASSMAR, Mehdi, et al.
Publicado: (2016)

CA125 and Ovarian Cancer: A Comprehensive Review
por: Charkhchi, Parsa, et al.
Publicado: (2020)

Comparison of diagnostic values between CA125 combined with CA199 and ultrasound combined with CT in ovarian cancer
por: Guo, Bingcheng, et al.
Publicado: (2019)

The Clinical Significance of CEA, CA19–9, and CA125 in Management of Appendiceal Adenocarcinoma
por: Yousef, Abdelrahman, et al.
Publicado: (2023)

The Performance of HE4 Alone and in Combination with CA125 for the Detection of Ovarian Cancer in an Enriched Primary Care Population
por: Barr, Chloe E., et al.
Publicado: (2022)

Prognostic Value of CEA, CA19-9, CA125, CA724, and CA242 in Serum and Ascites in Pseudomyxoma Peritonei
por: Liang, Lei, et al.
Publicado: (2021)

Menstrual Cycle Dependent Variability for Serum Tumor Markers CEA, AFP, CA 19-9, CA 125 and CA 15-3 in Healthy Women
por: Erbağci, Ayşe Binnur, et al.
Publicado: (1999)

Diagnostic and prognostic value of CEA, CA19–9, AFP and CA125 for early gastric cancer
por: Feng, Fan, et al.
Publicado: (2017)

CA125 in ovarian tumour tissue at second laparotomy.
por: Maughan, T. S., et al.
Publicado: (1989)

Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy
por: Sun, Zhipeng, et al.
Publicado: (2014)

CA-125 is not a useful marker in metastatic breast cancer.
por: Seckl, M. J., et al.
Publicado: (1992)

Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors
por: Chen, Fawen, et al.
Publicado: (2018)

Deciphering the Molecular Nature of Ovarian Cancer Biomarker CA125
por: Weiland, Florian, et al.
Publicado: (2012)

Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma
por: Wang, Wei, et al.
Publicado: (2016)

CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma
por: Isaksson, Sofi, et al.
Publicado: (2017)

The Diagnostic Accuracy of Combined Enolase/Cr, CA125, and CA19-9 in the Detection of Endometriosis
por: Rokhgireh, Samaneh, et al.
Publicado: (2020)

HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases
por: Molina, Rafael, et al.
Publicado: (2011)

Clinical significance and diagnostic value of serum NSE, CEA, CA19-9, CA125 and CA242 levels in colorectal cancer
por: Luo, Hai, et al.
Publicado: (2020)

Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?
por: Rustin, G. J. S., et al.
Publicado: (2016)

HE4, CA-125, and cystic ovarian mass
por: Wiwanitkit, Viroj
Publicado: (2012)

Relationship of tumor marker CA125 and ovarian tumor stem cells: preliminary identification
por: Zhang, Hui, et al.
Publicado: (2015)

Predictive equation of metastasis in patients with malignant ovarian epithelial tumors with the Ca-125 marker
por: Sánchez Vega, Juan Fernando, et al.
Publicado: (2018)

Prevalence of K-RAS mutations and CA125 tumor marker in patients with ovarian carcinoma
por: Bagherlou, Nazanin, et al.
Publicado: (2020)

A Panel of CA19-9, Ca125, and Ca15-3 as the Enhanced Test for the Differential Diagnosis of the Pancreatic Lesion
por: Hogendorf, Piotr, et al.
Publicado: (2017)

Clinical Significance of Serum CA125, CA19-9, CA72-4, and Fibrinogen-to-Lymphocyte Ratio in Gastric Cancer With Peritoneal Dissemination
por: Huang, Chao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dqibqh1135bvj7o3i67jr2ff8o